celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. celldex therapeutics (nasdaq: cldx) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. the company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. this has created a leading pipeline in im

Company profile
Ticker
CLDX
Exchange
Website
CEO
Anthony Marucci
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AVANT IMMUNOTHERAPEUTICS INC, T CELL SCIENCES INC
SEC CIK
Corporate docs
Subsidiaries
Celldex Therapeutics Switzerland GmbH ...
IRS number
133191702
CLDX stock data
Latest filings (excl ownership)
8-K
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
8 Nov 23
424B5
Prospectus supplement for primary offering
8 Nov 23
424B5
Prospectus supplement for primary offering
7 Nov 23
8-K
Other Events
6 Nov 23
S-3ASR
Automatic shelf registration
3 Nov 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
2 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
8 Aug 23
S-8
Registration of securities for employees
21 Jun 23
Latest ownership filings
SC 13G
Point72 Asset Management, L.P.
20 Nov 23
4
Diane C. Young
20 Jun 23
4
Richard M. Wright
20 Jun 23
4
RONALD PEPIN
20 Jun 23
4
Samuel Bates Martin
20 Jun 23
4
Freddy A. Jimenez
20 Jun 23
4
Margo Heath-Chiozzi
20 Jun 23
4
Elizabeth Crowley
20 Jun 23
4
Sarah Cavanaugh
20 Jun 23
4
TIBOR KELER
20 Jun 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 21.13 mm | 21.13 mm | 21.13 mm | 21.13 mm | 21.13 mm | 21.13 mm |
Cash burn (monthly) | 2.36 mm | (no burn) | 13.75 mm | 11.23 mm | 6.33 mm | 8.04 mm |
Cash used (since last report) | 5.45 mm | n/a | 31.69 mm | 25.90 mm | 14.59 mm | 18.54 mm |
Cash remaining | 15.69 mm | n/a | -10.56 mm | -4.76 mm | 6.54 mm | 2.59 mm |
Runway (months of cash) | 6.6 | n/a | -0.8 | -0.4 | 1.0 | 0.3 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 143 |
Opened positions | 17 |
Closed positions | 23 |
Increased positions | 60 |
Reduced positions | 42 |
13F shares | Current |
---|---|
Total value | 1.38 tn |
Total shares | 50.54 mm |
Total puts | 488.67 k |
Total calls | 565.30 k |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
FMR | 7.09 mm | $195.09 bn |
Wellington Management | 5.43 mm | $149.48 bn |
RTW Investments | 3.46 mm | $95.31 bn |
BLK Blackrock | 3.25 mm | $89.49 bn |
Kynam Capital Management | 3.20 mm | $88.06 bn |
Vanguard | 2.62 mm | $72.06 bn |
Polar Capital | 2.43 mm | $66.78 bn |
STT State Street | 2.29 mm | $63.10 bn |
BLVGF Bellevue | 1.90 mm | $52.29 bn |
Pictet Asset Management Holding | 1.85 mm | $50.94 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Jun 23 | Shoos Karen L. | NQSO Common Stock | Grant | Acquire A | No | No | 36.87 | 11,300 | 416.63 k | 11,300 |
15 Jun 23 | Cohen Cheryl | NQSO Common Stock | Grant | Acquire A | No | No | 36.87 | 11,300 | 416.63 k | 11,300 |
15 Jun 23 | Marino James J | NQSO Common Stock | Grant | Acquire A | No | No | 36.87 | 11,300 | 416.63 k | 11,300 |
15 Jun 23 | Conrad Herbert J | NQSO Common Stock | Grant | Acquire A | No | No | 36.87 | 11,300 | 416.63 k | 11,300 |
15 Jun 23 | Neil Garry Arthur | NQSO Common Stock | Grant | Acquire A | No | No | 36.87 | 11,300 | 416.63 k | 11,300 |
News
What 7 Analyst Ratings Have To Say About Celldex Therapeutics
10 Nov 23
Wells Fargo Upgrades Celldex Therapeutics to Equal-Weight, Announces $27 Price Target
10 Nov 23
Why Celldex Therapeutics (CLDX) Stock Is Getting Hammered
8 Nov 23
Celldex Therapeutics Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed
7 Nov 23
Why Bluegreen Vacations Shares Are Trading Higher By Around 105%? Here Are Other Stocks Moving In Monday's Mid-Day Session
6 Nov 23
Press releases
Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference
27 Nov 23
Celldex Therapeutics Announces Pricing of Public Offering of Common Stock
7 Nov 23
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
7 Nov 23
Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
6 Nov 23
Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab
5 Nov 23